These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 2786033

  • 1. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY.
    J Immunol; 1989 Jun 15; 142(12):4441-9. PubMed ID: 2786033
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY, Singleton A, Cillari E, Howard JG.
    J Immunol; 1985 Sep 15; 135(3):2102-7. PubMed ID: 3160786
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunization of susceptible hosts with a soluble antigen fraction from Leishmania major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells.
    Bogdan C, Schröppel K, Lohoff M, Röllinghoff M, Solbach W.
    Eur J Immunol; 1990 Dec 15; 20(12):2533-40. PubMed ID: 1980108
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection.
    Liew FY, Hale C, Howard JG.
    J Immunol; 1985 Sep 15; 135(3):2095-101. PubMed ID: 4020140
    [Abstract] [Full Text] [Related]

  • 8. Prophylactic immunization against experimental leishmaniasis. VI. Comparison of protective and disease-promoting T cells.
    Liew FY, Hodson K, Lelchuk R.
    J Immunol; 1987 Nov 01; 139(9):3112-7. PubMed ID: 3312413
    [Abstract] [Full Text] [Related]

  • 9. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 10. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens.
    Mazumdar T, Anam K, Ali N.
    J Parasitol; 2005 Apr 12; 91(2):269-74. PubMed ID: 15986599
    [Abstract] [Full Text] [Related]

  • 11. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
    Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F.
    Exp Parasitol; 2009 Apr 12; 121(4):362-9. PubMed ID: 19211022
    [Abstract] [Full Text] [Related]

  • 12. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract.
    Scott P, Pearce E, Natovitz P, Sher A.
    J Immunol; 1987 Nov 01; 139(9):3118-25. PubMed ID: 3499465
    [Abstract] [Full Text] [Related]

  • 13. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N, Afrin F.
    J Parasitol; 1997 Feb 01; 83(1):70-5. PubMed ID: 9057699
    [Abstract] [Full Text] [Related]

  • 14. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes.
    Scott P, Caspar P, Sher A.
    J Immunol; 1990 Feb 01; 144(3):1075-9. PubMed ID: 2295814
    [Abstract] [Full Text] [Related]

  • 15. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A, Jaafari MR, Khamesipour A.
    Exp Parasitol; 2007 Feb 01; 115(2):127-34. PubMed ID: 16979165
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY, Howard JG, Hale C.
    J Immunol; 1984 Jan 01; 132(1):456-61. PubMed ID: 6228580
    [Abstract] [Full Text] [Related]

  • 17. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, Mohammad O.
    Vaccine; 2006 Mar 10; 24(11):1800-10. PubMed ID: 16310900
    [Abstract] [Full Text] [Related]

  • 18. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N, Jaffe CL.
    J Immunol; 1993 Mar 15; 150(6):2322-31. PubMed ID: 8450215
    [Abstract] [Full Text] [Related]

  • 19. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major.
    Doherty TM, Coffman RL.
    J Immunol; 1993 Jun 15; 150(12):5476-83. PubMed ID: 8515072
    [Abstract] [Full Text] [Related]

  • 20. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.
    Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY.
    J Immunol; 1990 Oct 01; 145(7):2281-5. PubMed ID: 2144549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.